Vaccine-type mutations identified in Varicella zoster virus passaged in cell culture
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seok Cheon | - |
dc.contributor.author | Won, Youn Hee | - |
dc.contributor.author | Park, Ji Seon | - |
dc.contributor.author | Jeon, Jeong Seon | - |
dc.contributor.author | Ahn, Jin Hyun | - |
dc.contributor.author | Song, Moon Jung | - |
dc.contributor.author | Shin, Ok Sarah | - |
dc.contributor.author | Lee, Chan Hee | - |
dc.date.accessioned | 2021-09-02T15:03:57Z | - |
dc.date.available | 2021-09-02T15:03:57Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-02-02 | - |
dc.identifier.issn | 0168-1702 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/77388 | - |
dc.description.abstract | Varicella-zoster virus (VZV) is a causative agent for chickenpox and shingles. Comparative genomic sequence analysis of clinical and vaccine strains suggested potential sites responsible for attenuation. In this study, low and high passages of two VZV clinical strains cultured in human fibroblast cells were compared for genomic DNA sequences and growth characteristics. Mutations were detected at 187 and 162 sites in the strain YC01 and YC02, respectively. More than 86% of mutations were found in open reading frames, and ORF62 exhibited highest frequency of mutations. T to C and A to G transitions accounted for more 90% of all possible substitutions. Forty mutations were common to two strains, including 27 in ORF62. Mutations found in attenuated vaccine strains were also detected at 7 positions. Both high and low passage strains were infectious and grew similarly in human fibroblast cells. In guinea pig cells, however, high passage strain remained infectious while low passage strain lost infectivity. This study may provide new insight into the attenuating mutations associated with in vitro passaging of VZV. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | COMPLETE DNA-SEQUENCES | - |
dc.subject | EARLY PROTEIN IE62 | - |
dc.subject | VIRAL REPLICATION | - |
dc.subject | OKA VACCINE | - |
dc.subject | IN-VITRO | - |
dc.subject | STRAIN | - |
dc.subject | PATHOGENESIS | - |
dc.subject | GENE | - |
dc.subject | ATTENUATION | - |
dc.subject | INFECTIONS | - |
dc.title | Vaccine-type mutations identified in Varicella zoster virus passaged in cell culture | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Moon Jung | - |
dc.contributor.affiliatedAuthor | Shin, Ok Sarah | - |
dc.identifier.doi | 10.1016/j.virusres.2017.12.004 | - |
dc.identifier.scopusid | 2-s2.0-85039750229 | - |
dc.identifier.wosid | 000425196800007 | - |
dc.identifier.bibliographicCitation | VIRUS RESEARCH, v.245, pp.62 - 68 | - |
dc.relation.isPartOf | VIRUS RESEARCH | - |
dc.citation.title | VIRUS RESEARCH | - |
dc.citation.volume | 245 | - |
dc.citation.startPage | 62 | - |
dc.citation.endPage | 68 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | COMPLETE DNA-SEQUENCES | - |
dc.subject.keywordPlus | EARLY PROTEIN IE62 | - |
dc.subject.keywordPlus | VIRAL REPLICATION | - |
dc.subject.keywordPlus | OKA VACCINE | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | STRAIN | - |
dc.subject.keywordPlus | PATHOGENESIS | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | ATTENUATION | - |
dc.subject.keywordPlus | INFECTIONS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.